{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-023122","form_type":"8-K","ticker":"HCWB","cik":"0001828673","company_name":"HCW Biologics Inc.","filed_at":"2026-05-14T20:31:08+00:00","discovered_at":"2026-05-14T20:32:00.297984+00:00","generated_at":"2026-05-14T20:32:52.562485+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"HCW Biologics Q1 net income $3.5M on $6.5M revenue; reiterates going concern doubt, Nasdaq appeal pending","bullets":["Q1 2026 revenue $6.5M (vs $5K Q1 2025) from Trimmune license; net income $3.5M vs net loss $2.2M YoY.","Phase 1 HCW9302 for alopecia areata enrolling; preliminary data H1 2026, full readout Q4 2026; no DLTs.","Closed exclusive worldwide license with Beijing Trimmune for $3.5M cash plus $3.5M equity in-kind on March 16, 2026.","Going concern doubt exists; Nasdaq hearing granted May 5, 2026 to appeal delisting due to bid price non-compliance.","Completed $1.5M equity financing Feb 2026 with warrants at $0.6055 exercise price."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-023122","json":"https://secwatch.observer/filing/0001493152-26-023122.json","markdown":"https://secwatch.observer/filing/0001493152-26-023122.md","text":"https://secwatch.observer/filing/0001493152-26-023122.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828673/000149315226023122/0001493152-26-023122-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828673/000149315226023122/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T20:32:52.562485+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"80ca7c82d1e4f1969757243ca8e66aa76d72c16d","claim":"HCW Biologics Inc. reported the three months ended March 31, 2026 results: revenue $6.5 million, net income $3.5 million.","evidence_excerpt":"an in-kind payment of a transferable minority equity interest in Trimmune with a fair value of $3.5 million. For the three months ended March 31, 2026, the Company recognized $6.5 million in revenue and $470,000 in deferred revenue. Commercial-Ready Molecules Used as Reagents On March 13, 2026, Science Advances, a peer-reviewed, high-impact journal, released a","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828673/000149315226023122/0001493152-26-023122-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2026"},{"label":"Revenue","value":"$6.5 million"},{"label":"Net income","value":"$3.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}